What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
The scientist’s investigation covers issues in Cancer research, Pathology, Imatinib mesylate, Imatinib and GiST.
Jonathan A. Fletcher has researched Cancer research in several fields, including Carcinogenesis, Proto-Oncogene Proteins c-kit and Receptor tyrosine kinase.
His studies deal with areas such as Fluorescence in situ hybridization, Gene rearrangement, Fusion gene and Karyotype as well as Pathology.
His biological study deals with issues like Stromal tumor, which deal with fields such as Survival rate.
As a member of one scientific family, Jonathan A. Fletcher mostly works in the field of Imatinib, focusing on Oncology and, on occasion, Surgery.
His study in GiST is interdisciplinary in nature, drawing from both Sunitinib, Tyrosine kinase, Protein kinase B and Tyrosine-kinase inhibitor.
His most cited work include:
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (3544 citations)
- The landscape of somatic copy-number alteration across human cancers (2544 citations)
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor (1920 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Cancer research, Pathology, GiST, Imatinib and Internal medicine.
The Cancer research study which covers Receptor tyrosine kinase that intersects with Protein kinase B.
The concepts of his Pathology study are interwoven with issues in Fluorescence in situ hybridization, Karyotype and Cytogenetics.
His GiST research incorporates elements of Sunitinib, Immunology, Stromal tumor and Tyrosine-kinase inhibitor.
His work in Imatinib tackles topics such as PI3K/AKT/mTOR pathway which are related to areas like MAPK/ERK pathway.
He interconnects Gastroenterology, Endocrinology, Surgery and Oncology in the investigation of issues within Internal medicine.
He most often published in these fields:
- Cancer research (52.93%)
- Pathology (39.33%)
- GiST (25.10%)
What were the highlights of his more recent work (between 2014-2021)?
- Cancer research (52.93%)
- GiST (25.10%)
- Imatinib (21.34%)
In recent papers he was focusing on the following fields of study:
Jonathan A. Fletcher spends much of his time researching Cancer research, GiST, Imatinib, PDGFRA and Pathology.
His biological study focuses on Stromal cell.
His study looks at the relationship between Stromal cell and fields such as Tyrosine-kinase inhibitor, as well as how they intersect with chemical problems.
His GiST research is multidisciplinary, incorporating elements of Sunitinib, Receptor tyrosine kinase, Stromal tumor and PI3K/AKT/mTOR pathway.
His Imatinib study combines topics from a wide range of disciplines, such as Mutation, Drug resistance and Oncology.
His biological study spans a wide range of topics, including CDKN2A and Doxorubicin.
Between 2014 and 2021, his most popular works were:
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma (180 citations)
- Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition (67 citations)
- Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. (65 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His primary areas of investigation include Cancer research, GiST, Imatinib, Imatinib mesylate and Pathology.
His Cancer research study integrates concerns from other disciplines, such as Immunohistochemistry, Mutation, Sarcoma, Rhabdomyosarcoma and Cell cycle.
In the subject of general GiST, his work in PDGFRA is often linked to Regorafenib, thereby combining diverse domains of study.
His Imatinib study which covers Cancer that intersects with Gerontology.
The various areas that Jonathan A. Fletcher examines in his Imatinib mesylate study include Clinical trial, Phases of clinical research, Surgery and Oncology.
He has researched Pathology in several fields, including Cell and TFE3.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
